The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34890968/
Multiple myeloma is a haematological malignancy that is dependent upon interactions within the bone microenvironment to drive tumour growth and osteolytic bone disease. Metformin is an anti-diabetic drug that has...
Conclusion/Relevance: Metformin is an anti-diabetic drug that has attracted attention due to its direct antitumor effects, including anti-myeloma properties. However, the impact of the bone microenvironment on the response to metformin in myeloma is unknown. We have employed in vitro and in vivo models to dissect out the direct effects of...
Super enhancer-mediated upregulation of HJURP promotes growth and survival of t(4;14)-positive multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34893510/
Multiple myeloma (MM) is an incurable malignancy with marked clinical and genetic heterogeneity. The cytogenetic abnormality t(4;14) (p16.3;q32.3) confers aggressive behavior in MM. Recently, essential oncogenic drivers in a wide...
Conclusion/Relevance: In summary, this study introduces SE profiling as an efficient approach to identify new targets and understand molecular pathogenesis in specific subtypes of cancer. Moreover, HJURP could be a valuable therapeutic target in t(4;14)-positive myeloma patients.
Modeling Pharmacokinetics of Doxorubicin in Multiple Myeloma Cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34892189/
Doxorubicin (DOXO) is a well-established chemotherapy drug for treatment of different tumors, ranging from breast cancer, melanoma to multiple myeloma (MM). Here, we present a coupled experimental/modeling approach to study...
Relevance: The model can be used to properly understand and guide further experimental setup, e.g., to investigate multiple myeloma cell variability among different cell lines.
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34854741/
Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma...
Conclusion/Relevance:This paper reviews the ide-cel product in terms of design, pharmacology, efficacy and toxicity as described in studies reported to date.
Absolute lymphocyte count prior lymphodepletion impacts outcomes in multiple myeloma patients treated with CAR-T cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34861455/
1 Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem...
Conclusion: In conclusion, pre-LD ALC could be a useful indicator to predict the outcomes of CAR-T cell therapy in patients with R/R MM.